J�r�me Couturier
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer
Couturier, J�r�me; Balaton, Andr� J.; Rhodes, Anthony; Jasani, Bharat; McKinley, Mark J.; Morgan, John M.; Dodson, Andrew R.; Navabi, Hossein; Balaton, Andre J.; Miller, Keith D.
Authors
Andr� J. Balaton
Anthony Rhodes
Bharat Jasani
Mark J. McKinley
John M. Morgan
Andrew R. Dodson
Hossein Navabi
Andre J. Balaton
Keith D. Miller
Abstract
To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside Hercep Test kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1+ staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.
Citation
Balaton, A. J., Couturier, J., Rhodes, A., Jasani, B., McKinley, M. J., Morgan, J. M., …Balaton, A. J. (2002). A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. American Journal of Clinical Pathology, 117(1), 81-89. https://doi.org/10.1309/4NCM-QJ9W-QM0J-6QJE
Journal Article Type | Article |
---|---|
Publication Date | Jan 21, 2002 |
Journal | American Journal of Clinical Pathology |
Print ISSN | 1943-7722 |
Publisher | Oxford University Press (OUP) |
Peer Reviewed | Peer Reviewed |
Volume | 117 |
Issue | 1 |
Pages | 81-89 |
DOI | https://doi.org/10.1309/4NCM-QJ9W-QM0J-6QJE |
Keywords | breast cancer, HER-2/neu, cell line standard, immunohistochemistry, fluorescence in situ hybridization, quality control |
Public URL | https://uwe-repository.worktribe.com/output/1083700 |
Publisher URL | http://dx.doi.org/10.1309/4NCM-QJ9W-QM0J-6QJE |